Quantcast
Last updated on April 18, 2014 at 8:55 EDT

Latest National Institute for Health and Clinical Excellence Stories

2008-09-19 00:00:29

Why aren't drugs which could save or prolong the lives of cancer sufferers not being licensed for NHS use? That was the tough question being faced yesterday by NICE, the National Institute for Health and Clinical Excellence, at a special meeting in Plymouth, writes Sophie Roberts. Local people had the chance to hear about latest developments and quiz health bosses during an hour-long public question time. The audience included people with terminal illnesses and their partners, as well...

2008-09-19 00:00:10

Cancer sufferers in the South West were unhappy with the lack of answers they received at a meeting to discuss the use of life- prolonging drugs yesterday. Patients suffering with the disease attended a meeting with the National Institute of Clinical Excellence (NICE) in Plymouth to find out why drugs that prolong a person's life are not widely available on the NHS. Sutent has been rejected for use on the NHS because it is not seen as being cost effective and NICEs believe it only...

2008-09-10 18:00:08

By Martin Shipton A DAUGHTER whose father suffers from cancer has today appealed directly to Health Minister Edwina Hart for those in his position to be given the drugs that could prolong their lives. Anna Wolfenden's open letter to Ms Hart calls for a swift decision to be made about the availability of drugs such as Sunitinib that are widely available for patients with kidney cancer in the United States and other countries but have failed to secure the recommendation of NHS bodies in...

2008-09-10 12:00:51

BRIDGEWATER, N.J., Sept. 10 /PRNewswire/ -- Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry, today published a special issue of Adis PharmacoEconomics devoted to helping drug makers better understand the requirements behind the so-called "fourth hurdle" -- demonstrating a drug's reasonable cost effectiveness. The issue focuses on the...

2008-09-09 21:00:20

Professor Karol Sikora said the next generation of drugs would keep people alive for longer but they were so expensive they could swallow half of the current NHS budget within four years.He calculated they could cost the NHS 50bn around half the current budget, which tops 100bn.The professor, who is director of Cancer Partners UK, a private provider of cancer services that works with the NHS, came up with the figures for Sky News.He said: "50bn is the equivalent to raising tax by 15p for...

2008-09-09 18:00:32

By Jane Kirby THE high cost of cancer drugs could lead the NHS into "meltdown", a leading expert said today. Professor Karol Sikor a said the next generation of drugs would keep people alive for longer but they were so expensive they could swallow half of the current NHS budget within four years. He calculated they could cost the NHS pounds 50bn - around half the current budget, which tops pounds 100bn. The professor, who is director of Cancer Partners UK, a private provider of...

2008-09-08 15:00:00

By Helen Puttick IT is, perhaps, an unusual move; from an organisation which fought for patients to one that often faces accusations of acting against their interests. But Andy Powrie-Smith insists his surprise appointment as director of the Association of the British Pharmaceutical Industry is simply working for patients in a different way. The new director was, when the announcement was made, the head of a charity, the British Lung Foundation Scotland - which fights for patients...

2008-09-05 00:00:26

By Sadie Gray A cancer sufferer whose primary care trust refused to pay for a drug which could extend his life by up to three years has launched an "end of the road" legal challenge to the decision. If Colin Ross continues to be denied the drug, Revlimid, he will die within a few months, experts say. His lawyers told the High Court yesterday that he was the victim of a postcode lottery. Mr Ross, 55, said his doctors had requested funding for up to four courses of Revlimid at 5,000 a...

2008-09-04 12:00:32

With the cost of healthcare provision spiraling, governments and payers across the seven major markets are applying cost-cutting measures, putting even greater pressure on pharmaceutical companies. In the UK, the National Institute of Clinical Excellence recently rejected four new kidney cancer therapies on the basis of cost effectiveness, effectively denying patients access to these novel drugs. It is not just the credit crunch that is putting pharmaceutical companies under pressure....

2008-09-02 00:00:28

According to charity Infertility Network UK, North Staffordshire PCT is one of just three health authorities across the country which has suspended funding for IVF. The charity says 92 PCTs fund one cycle of treatment, 32 fund two and nine fund three cycles. The National Institute for Health and Clinical Excellence (NICE) recommends women aged between 23 and 39 receive three free cycles of fertility treatment on the NHS. Government guidance states PCTs should provide a minimum of one...